ORIC Pharmaceuticals, Inc. ORIC NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

59/100

3/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

ORIC Pharmaceuticals, Inc. (ORIC) generated $-22.48M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $387K, free cash flow was $-22.87M.

Cash conversion ratio was 0.74x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (40/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.74x suggests some earnings are non-cash items

Overall SharesGrow Score: 57/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

59/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

40/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

ORIC Pharmaceuticals, Inc. Cash Flow History

Metric	TTM	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Operating Cash Flow	$-110.97M	$-22.48M	$-25.11M	$-30.84M	$-32.53M
Capital Expenditure	$-485K	$-387K	$-35K	$-63K	$0.00
Free Cash Flow	$-111.46M	$-22.87M	$-25.15M	$-30.91M	$-32.53M